04/2020 Ventures

GNA has developed corona test

Our Munich-based portfolio company GNA Biosolutions is making its contribution to the fight against the corona virus and is also supported by the Bavarian Ministry of Economic Affairs in order to enable the market launch of the mobile test device within 8-12 weeks. GNA Biosolutions uses a novel detection method, which provides a reliable result regarding a possible COVID-19 disease within 15 minutes. With 1,000 devices about 300,000 tests could be performed daily.
In addition to the current challenges, the rapid diagnosis of highly infectious diseases will continue to provide a good database for the future in order to identify pandemic risks at an early stage and initiate appropriate measures.

More information can be found in the article in Süddeutsche Zeitung (text in German) under the following link.

More about GNA

03/2020 Group

OCCIDENT – digital and financially strong

As a company that has been digital for years, the conversion to home office in the course of COVID-19 was not difficult for us. Since mid-March, we have been keeping our physical distance responsibly and considerately, but we are still making a digital effort to promote interpersonal exchange and cohesion during the crisis. During this time, it becomes particularly clear how important the digitalization of our processes and the solidarity towards our fellow human beings are.
For years, OCCIDENT has been investing in start-ups that make digital and medical progress possible and thus represent added value for society. As a financially strong and entrepreneurial investor, we will continue to support start-ups. Especially in the current crisis, we take our responsibility seriously and continue to be a trustworthy partner for visionary founders.
Stay healthy and take care of yourself!

02/2020 Ventures

Follow-up Investment in Lunaphore

Already for the third time, Occident participates in a financing round for the Swiss diagnostics company Lunaphore, which revolutionizes tumor diagnostics with its technology. Following the successful market launch of LabSat, the new funds will flow into the company’s growth and internationalization, as well as into new innovations.

More information can be found in the press release under the following link.

More about Lunaphore

01/2020 Ventures

News advanceCOR

Congratulations to advanceCOR! With its lead compound Revacept, our portfolio company was able to prevent the local activation of blood platelets at sites of vascular injury in carotid stenosis patients in a phase II clinical trial and thereby achieving an almost 50% reduction in new silent strokes (microinfarctions). More information can be found in the press release under the following link.

More about advanceCOR

01/2020 Ventures

Successful exit Cunesoft

We are happy to start the new year with great news. After nearly four years of investing in Cunesoft and supporting the exciting development of digital data management in the healthcare sector, we could realize a successful exit. With Phlexglobal, Cunesoft has found a perfect match for its further internationalization of its unique software solution. We congratulate the founders and the whole team and wish them all the best!

More information can be found in the press release under the following link.

01/2020 Group

We are climate neutral

Also at the beginning of the year 2020, climate change and its negative consequences are more present than ever. As a sustainable company, this issue is important to us, which is why we also want to make our contribution to climate protection. We have calculated our CO2 corporate balance for the year 2019 and, based on this, support projects to reduce carbon dioxide emissions in cooperation with the Swiss foundation myclimate.

More about myclimate

12/2019 Group

When you raise your eyes, you see no boundaries

(Japanese proverb)

We would like to make ourselves aware at the end of the year that in a fast-moving and continuously success-oriented time it is always necessary to pause for a moment in order to actually be able to realize the unlimited potential of innovation.

With this in mind, we would like to thank you for the enriching and inspiring cooperation and look forward to working together in the future to raise our eyes and improve tomorrow‘s life sustainably through meaningful investments.

We wish you a peaceful, inspiring Christmas season and a fantastic year in 2020.

12/2019 Ventures

Follow-on Investment in Resistell

Resistell closes the year successfully with Occident as lead investor in the Series A financing round. Founded in 2018, the start-up is dedicated to the precise and rapid identification of antibiotic resistance. In order to advance clinical validation and marketing approval, additional funding was provided by existing and new investors. More information can be found in the press release under the following link.

More about Resistell 

Show more